Where we are today
Percentage of breast/ovarian and colon cancer patients who were eligible and received a hereditary cancer screen (10- or 12-gene panel), and percentage of colorectal cancer patients diagnosed within a two-year period who had a completed tumour tissue screen for Lynch Syndrome (MMR testing).
Data source: Provincial cancer agencies and programs
Note:
- The COVID-19 pandemic may have affected service provision.
- Eligibility for hereditary cancer screens include patients with no known pathogenic familial variant and who meet panel testing criteria. Individuals who do not meet this eligibility criteria include those with a familial mutation who will receive genetic testing for the mutation of interest only or those who do not meet full criteria for the 10- or 12-gene panel but may have other genetic testing panels completed (e.g., individuals meeting specific ethnic requirements for variants common in that population).
Click here to see all data and data limitations, including any additional stratifications.